Research programme: anti-ganglioside GD2 monoclonal antibodies - BioWa
Alternative Names: BIW-8137; KM-8138; POTELLIGENT-GD2Latest Information Update: 05 Nov 2023
At a glance
- Originator BioWa
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 24 Oct 2008 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 03 Mar 2004 Anti-ganglioside GD-2 monoclonal antibody is available for licensing in Europe, North America and South America (http://www.biowa.com)
- 11 Aug 2003 Preclinical trials in Solid tumours in USA (unspecified route)